Fairvalue-Calculator Fairvalue-Calculator
EN DE

Deltex Medical Group (DTXMF) Fair Value & Analysis

Healthcare · US · Market cap $181M

Price$0.0952
Fair Value$0.0100
Upside-89.5%
Quality87/100
Evidence: Low

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Deltex Medical Group (DTXMF) currently trades at $0.0952, while our model-based Fair Value estimate is $0.0100 — implying the stock looks roughly 89.5% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler and pulse contour analysis and monitoring platform. It offers dopplink, a patient interface cable; and pressurewave, an arterial blood pressure signal under the TrueVue brand. The company also provides oesophageal doppler monitoring systems. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -81% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Deltex Medical Group (DTXMF) undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.0100 versus a price of $0.0952 — about −89% (overvalued). Model-based estimate, not financial advice.
What is the fair value of DTXMF?
Our 21-model fair value for Deltex Medical Group is $0.0100 (as of Jun 23, 2026), built from audited fundamentals. The current price is $0.0952.
What is the quality score of DTXMF?
Deltex Medical Group has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.